MGLL and Hepatic fibrosis: In liver fibrosis mouse models induced by BDL or CCl4, PET using a probe targeting MAGL, the F-18-labeled MAGL inhibitor ([18F]MAGL-4-11), was performed to evaluate the expression levels of MAGL, and significant signal diminution was observed at the early stage of liver fibrosis, which further decreased with disease progression [100].